12012 — MIMEDI (Q3698691): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in es, and other parts: Adding Spanish translations)
(‎Merged Item from Q190706)
aliases / en / 0aliases / en / 0
 
12012 – MIMEDI
description / frdescription / fr
 
Projet Q190706 en France
Property / French Kohesio ID
 
10341
Property / French Kohesio ID: 10341 / rank
 
Normal rank
Property / summary
 
Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English)
Property / summary: Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English) / rank
 
Normal rank
Property / summary: Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English) / qualifier
 
point in time: 13 October 2020
Timestamp+2020-10-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / summary
 
Recentemente sono emersi medicinali innovativi (medii) al fine di offrire nuove soluzioni terapeutiche ai pazienti con impasse terapeutica. Questi medicinali sono basati sull'uso di cellule "farmaci". Tuttavia, la produzione di questi farmaci richiede l'attuazione di tecnologie complesse e quindi costose. L'ambizione di MiMédi è di razionalizzare la loro produzione fornendo nuove soluzioni tecniche e ottimizzando tutte le fasi necessarie per la loro produzione. Per fare questo, MiMédi combina laboratori di ricerca e industria sia di ingegneria che di ingegneria cellulare. (Italian)
Property / summary: Recentemente sono emersi medicinali innovativi (medii) al fine di offrire nuove soluzioni terapeutiche ai pazienti con impasse terapeutica. Questi medicinali sono basati sull'uso di cellule "farmaci". Tuttavia, la produzione di questi farmaci richiede l'attuazione di tecnologie complesse e quindi costose. L'ambizione di MiMédi è di razionalizzare la loro produzione fornendo nuove soluzioni tecniche e ottimizzando tutte le fasi necessarie per la loro produzione. Per fare questo, MiMédi combina laboratori di ricerca e industria sia di ingegneria che di ingegneria cellulare. (Italian) / rank
 
Normal rank
Property / summary: Recentemente sono emersi medicinali innovativi (medii) al fine di offrire nuove soluzioni terapeutiche ai pazienti con impasse terapeutica. Questi medicinali sono basati sull'uso di cellule "farmaci". Tuttavia, la produzione di questi farmaci richiede l'attuazione di tecnologie complesse e quindi costose. L'ambizione di MiMédi è di razionalizzare la loro produzione fornendo nuove soluzioni tecniche e ottimizzando tutte le fasi necessarie per la loro produzione. Per fare questo, MiMédi combina laboratori di ricerca e industria sia di ingegneria che di ingegneria cellulare. (Italian) / qualifier
 
point in time: 12 January 2022
Timestamp+2022-01-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / postal code
 
25030
Property / postal code: 25030 / rank
 
Normal rank
Property / coordinate location
 
47°14'23.03"N, 6°0'44.14"E
Latitude47.239733666667
Longitude6.0122559333333
Precision1.0E-5
Globehttp://www.wikidata.org/entity/Q2
Property / coordinate location: 47°14'23.03"N, 6°0'44.14"E / rank
 
Normal rank
Property / ID used by InfoRegio
 
4607
Property / ID used by InfoRegio: 4607 / rank
 
Normal rank
Property / info Regio url
 
Property / info Regio url: https://ec.europa.eu/regional_policy/en/projects/europe/mimedi-optimiser-la-fabrication-de-medicaments-innovants-en-evitant-le-recours-aux-salles-blanches / rank
 
Normal rank
Property / image url
 
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / rank
 
Normal rank
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / qualifier
 
summary: Device for biological element sorting by acoustophoresis. (English)
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / qualifier
 
copyright: Quarroz – FEMTO, Univ-Franche-Comte 2018
Property / contained in NUTS
 
Property / contained in NUTS: Doubs / rank
 
Normal rank

Revision as of 13:44, 16 May 2022

Project Q3698691 in France
  • 12012 – MIMEDI
Language Label Description Also known as
English
12012 — MIMEDI
Project Q3698691 in France
  • 12012 – MIMEDI

Statements

contained in NUTS
Doubs
0 references
country
France
0 references
EU contribution
10,211,026.83 Euro
0 references
budget
13,614,711.32 Euro
0 references
co-financing rate
75.0 percent
0 references
start time
1 December 2017
0 references
end time
30 November 2021
0 references
beneficiary name (string)
Université de Franche-Comté
0 references
beneficiary
Q3771919
0 references
coordinate location

47°14'23.03"N, 6°0'44.14"E
0 references
postal code
25030
0 references
summary
Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
0 references
Innovative (medium) medicines have recently emerged in order to offer new treatment solutions for patients with therapeutic impasses. These medicinal products are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi’s ambition is to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do this, MiMédi combines research laboratories and industry from both engineering and cellular engineering. (English)
point in time
22 November 2021
0 references
Innovative (Medien-)Arzneimittel sind in jüngster Zeit entstanden, um neue Behandlungslösungen für Patienten in therapeutischen Sackgassen anzubieten. Diese Arzneimittel basieren auf der Verwendung von „Arzneimitteln“ Zellen. Die Herstellung dieser Arzneimittel erfordert jedoch die Anwendung komplexer und damit kostspieliger Technologien. MiMédi hat sich zum Ziel gesetzt, ihre Fertigung zu rationalisieren, indem sie neue technische Lösungen bereitstellt und alle für ihre Produktion erforderlichen Schritte optimiert. MiMédi verbindet Forschungslabore und Franc-Comtoi-Industrien aus den Ingenieur- und Zellwissenschaften. (German)
point in time
1 December 2021
0 references
Er zijn onlangs innovatieve (middelmatige) geneesmiddelen ontstaan om nieuwe behandelingsoplossingen te bieden aan patiënten met therapeutische impasses. Deze geneesmiddelen zijn gebaseerd op het gebruik van „geneesmiddelen” cellen. Voor de vervaardiging van deze geneesmiddelen zijn echter complexe en dus dure technologieën nodig. De ambitie van MiMédi is om hun productie te stroomlijnen door nieuwe technische oplossingen te bieden en alle stappen te optimaliseren die nodig zijn voor hun productie. Hiervoor combineert MiMédi onderzoekslaboratoria en industrie uit zowel engineering als cellulaire engineering. (Dutch)
point in time
6 December 2021
0 references
Recentemente sono emersi medicinali innovativi (medii) al fine di offrire nuove soluzioni terapeutiche ai pazienti con impasse terapeutica. Questi medicinali sono basati sull'uso di cellule "farmaci". Tuttavia, la produzione di questi farmaci richiede l'attuazione di tecnologie complesse e quindi costose. L'ambizione di MiMédi è di razionalizzare la loro produzione fornendo nuove soluzioni tecniche e ottimizzando tutte le fasi necessarie per la loro produzione. Per fare questo, MiMédi combina laboratori di ricerca e industria sia di ingegneria che di ingegneria cellulare. (Italian)
point in time
13 January 2022
0 references
Recientemente han surgido medicamentos innovadores (medios) con el fin de ofrecer nuevas soluciones de tratamiento para pacientes con estancamientos terapéuticos. Estos medicamentos se basan en el uso de células «fármacas». Sin embargo, la fabricación de estos medicamentos requiere la aplicación de tecnologías complejas y, por lo tanto, costosas. La ambición de MiMédi es optimizar su fabricación proporcionando nuevas soluciones técnicas y optimizando todos los pasos necesarios para su producción. Para ello, MiMédi combina laboratorios de investigación e industria tanto de ingeniería como de ingeniería celular. (Spanish)
point in time
14 January 2022
0 references
Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English)
point in time
13 October 2020
0 references
Recentemente sono emersi medicinali innovativi (medii) al fine di offrire nuove soluzioni terapeutiche ai pazienti con impasse terapeutica. Questi medicinali sono basati sull'uso di cellule "farmaci". Tuttavia, la produzione di questi farmaci richiede l'attuazione di tecnologie complesse e quindi costose. L'ambizione di MiMédi è di razionalizzare la loro produzione fornendo nuove soluzioni tecniche e ottimizzando tutte le fasi necessarie per la loro produzione. Per fare questo, MiMédi combina laboratori di ricerca e industria sia di ingegneria che di ingegneria cellulare. (Italian)
point in time
12 January 2022
0 references
image url
https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg
summary
Device for biological element sorting by acoustophoresis. (English)
copyright
Quarroz – FEMTO, Univ-Franche-Comte 2018
0 references

Identifiers

French Kohesio ID
FC0013440
0 references
10341
0 references
ID used by InfoRegio
4607
0 references
 
Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3698691&oldid=28465537"